Eli Lilly’s revenue surge widens the gap with Bristol Myers Squibb as Mounjaro and Zepbound keep pulling results

Eli Lilly’s growth has become harder to ignore in the crowded obesity and diabetes drug market, according to a new market-focused comparison of two major pharma companies. The analysis points to a clear divergence: Lilly’s revenue nearly doubled over a roughly two-year period, while Bristol Myers Squibb’s revenue was described as relatively flat, widening the distance between the companies’ financial trajectories.

The widening gap is being attributed to the performance of Lilly’s tirzepatide franchise, particularly Mounjaro and Zepbound. Mounjaro is a once-weekly treatment used for type 2 diabetes, and Zepbound is Lilly’s once-weekly obesity, or weight-loss, medicine based on the same underlying drug class approach. The central argument in the comparison is that these products have continued to translate into stronger revenue momentum for Lilly.

By contrast, the comparison frames Bristol Myers Squibb as having less direct exposure to the specific growth engine driving Lilly’s sales. With BMY’s revenue characterized as relatively flat in the period reviewed, the article suggests that investors are increasingly measuring the “obesity factor” in pharma results, not just broader category exposure. In practical terms, companies with GLP-1 and next-generation GLP-1-style medicines have been rewarded more consistently as demand has expanded.

While the market comparison emphasizes the magnitude of the difference, it also implicitly raises a question that investors care about: how long can Lilly keep “juicing” results from its GLP-1 lineup? That concern matters because the GLP-1 obesity market is still young, and growth rates can change as supply ramps, pricing and reimbursement evolve, and competitors bring forward their own alternatives. The post does not provide a timeline for exactly when Lilly’s growth might slow, but it frames the continuing strength as the key variable to watch.

The comparison also lands in a broader sector context where obesity drugs have become a capital allocation and pipeline credibility test for pharma companies. Revenue momentum can reinforce market confidence, helping firms fund additional clinical development, manufacturing expansions, and geographic rollout. For companies without comparable late-stage obesity assets, the market dynamic is more challenging because results can look structurally constrained even when other segments perform.

Still, important details are not laid out in the market post. It does not specify the exact revenue figures, quarter-by-quarter breakdowns, or which products and geographies are driving the “flat” characterization for Bristol Myers Squibb. It also does not disclose any company management commentary, guidance updates, or formal guidance ranges tied directly to these numbers in the excerpt provided. That means readers should treat the comparison as a high-level financial snapshot rather than a fully sourced earnings analysis.

Looking ahead, what to watch is whether Lilly can sustain broad-based demand while managing key business constraints tied to GLP-1-style therapies, including production capacity and reimbursement conditions. For Bristol Myers Squibb, the question is whether it can accelerate growth through other pipeline bets, partnerships, or competitive responses. The next major datapoints will likely be company earnings releases that detail segment performance, supply and demand commentary, and updates on how durable obesity-related sales trends will be over the coming quarters.